Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Mammal patents



      
           
This page is updated frequently with new Mammal-related patent applications. Subscribe to the Mammal RSS feed to automatically get the update: related Mammal RSS feeds. RSS updates for this page: Mammal RSS RSS



Date/App# patent app List of recent Mammal-related patents
07/30/15
20150215127 
 Method of secure communication utilizing a cryptographic neural implant for reception of visual system signals patent thumbnailnew patent Method of secure communication utilizing a cryptographic neural implant for reception of visual system signals
A method for the secure communication of sensitive information in which the receiver of the sensitive information is equipped with a neural implant capable of stimulating the visual system of a mammalian brain. In this method, a transmitting party encrypts an image or a sequence of images and sends them to a computational device or devices securely connected to the receiving party's neural implant.
Neurocryptonics Innovations L.l.c.


07/30/15
20150212084 
 Specific removal of activated immune cells patent thumbnailnew patent Specific removal of activated immune cells
The present invention provides a method of detecting an immune response in a mammalian subject by: (a) withdrawing blood or a blood fraction containing immune cells from the subject; (b) contacting the blood or blood fraction to an antibody (e.g., a monoclonal antibody) that specifically binds to the cell surface hla-f histocompatibility protein of activated mammalian immune cells, which antibody does not bind to the cell surface of non-activated mammalian immune cells; and then (c) detecting the presence or absence of binding of the immune cells to the antibody, the presence of binding indicating the presence of an immune response in the subject. A further aspect of the invention is a composition comprising, consisting of or consisting essentially of a solid support having an antibody (e.g., a monoclonal antibody) coupled thereto, which antibody specifically binds to the cell surface hla-f histocompatibility protein of activated mammalian t-lymphocytes, and which antibody does not bind to the—cell surface of non-activated mammalian t-lymphocytes.
The Fred Hutchinson Cancer Research Center


07/30/15
20150211020 
 Complex chromosome engineering for production of human antibodies in transgenic animals patent thumbnailnew patent Complex chromosome engineering for production of human antibodies in transgenic animals
The invention relates to large-scale production of human antibodies by transgenic animals with high production of fully human igg up to >10 g/l in sera with human igg1 subclass dominancy. This invention also supports a feasibility of complex chromosome engineering for complicated genetic studies in non-murine mammalian species..
Sab, Llc


07/30/15
20150210992 
 Method for production of recombinant human alpha-galactosidase a patent thumbnailnew patent Method for production of recombinant human alpha-galactosidase a
Disclosed is a method for production of recombinant human alpha-galactosidase a (rh alpha-gal a) in a large scale, with a high purity. The method comprises the steps of (a) culturing rh alpha-gal a-producing mammalian cells in a serum-free medium, (b) collecting culture supernatant, (c) subjecting the culture supernatant to anion-exchange column chromatography, (d) to hydrophobic column chromatography, (e) to a column chromatography employing as solid phase a material having affinity for phosphate group, (f) to cation-exchange column chromatography, and (g) to gel filtration column chromatography, in the order..
Jcr Pharmaceuticals Co., Ltd.


07/30/15
20150210985 
 Generation of patient-specific differentiated cell types by epigenetic induction patent thumbnailnew patent Generation of patient-specific differentiated cell types by epigenetic induction
Disclosure of a mammalian cytoplasmic donor cell line. Disclosure of a patient specific cell line.

07/30/15
20150210983 
 Maintenance and propagation of mesenchymal stem cells patent thumbnailnew patent Maintenance and propagation of mesenchymal stem cells
Various embodiments of the present invention include compositions, materials and methods for maintaining and propagating mammalian mesenchymal stem cells in an undifferentiated stale in the absence of feeder cells and applications of the same.. .
The United States Of America As Represented By The Department Of Veterans Affairs


07/30/15
20150210980 
 System for in-situ management of ph of culture patent thumbnailnew patent System for in-situ management of ph of culture
Disclosed is a hydrogel composition loaded with a base that regulates and maintains the ph of cell culture media. The invention particularly discloses in situ ph managing hydrogels (phmh) loaded with base mg(oh)2 for ph control in small scale cultures comprising adherent mammalian cells, suspended mammalian cells, microorganisms, a microorganism with plasmids and the like thereof..
Council Of Scientific & Industrial Research


07/30/15
20150210727 
 Compounds and methods for treating mammalian gastrointestinal microbial infections patent thumbnailnew patent Compounds and methods for treating mammalian gastrointestinal microbial infections
Disclosed are compounds and pharmaceutically acceptable salts thereof, which are useful as inhibitors of impdh. In certain embodiments, a compound selectively inhibits a parasitic impdh versus a host impdh.
The Brigham And Women's Hospital, Inc.


07/30/15
20150210626 
 Cycloalkyl-diamines patent thumbnailnew patent Cycloalkyl-diamines
The invention is directed to a compound of formula i, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula i, a method of treatment of a disorder or condition that may be treated by administration of the compound, the method comprising administering to a mammal, especially a human, in need of such treatment a compound of formula i as described above, and a method of treatment of a disorder or condition selected from the group consisting human african trypanosomiasis (hat), chagas disease, malaria, leishmaniasis, and other infectious diseases transmitted to humans and animals by exposure to parasites, the method comprising administering to a human or mammal in need of such treatment a compound of formula i as described above.. .

07/30/15
20150209482 
 Cross-linked fatty acid-based biomaterials patent thumbnailnew patent Cross-linked fatty acid-based biomaterials
Fatty acid-based, pre-cure-derived biomaterials, methods of making the biomaterials, and methods of using them as drug delivery carriers are described. The fatty acid-derived biomaterials can be utilized alone or in combination with a medical device for the release and local delivery of one or more therapeutic agents.
Atrium Medical Corporation


07/30/15
20150209478 
new patent

Articles for tissue regeneration with biodegradable polymer


The invention is to articles made from extracellular matrix sheets that encase biodegradable polymeric material. Methods of healing wounds or regenerating tissue at sites of defect by placing said articles in mammals are claimed.
Cormatrix Cardiovascular, Inc.


07/30/15
20150209441 
new patent

Anandamide-modified nucleic acid molecules


The present invention refers to a conjugate comprising at least one polyunsaturated fatty acid residue, particularly an arachidonic acid residue, more particularly an anandamide (arachidonoyl ethanol amide) residue and covalently bound thereto at least one nucleosidic component selected from nucleic acids, nucleosides and nucleotides. This conjugate is suitable for the transfection of cells such as mammalian cells including human cells with high efficacy.
Baseclick Gmbh


07/30/15
20150209435 
new patent

Aqueous drug delivery system


Novel water stable pharmaceutical compositions, their liquid form oral pharmaceutical compositions and kits thereof, rehydration beverages containing these water stable pharmaceutical compositions methods of manufacture and methods of use thereof are disclosed. The novel aqueous delivery systems are useful, inter alia, as alternative pharmaceutical dosing agents to tablets, capsules and other forms of delivering medication to a mammalian host in need thereof..
Bev-rx, Inc.


07/30/15
20150209409 
new patent

Uses of il-12 in hematopoiesis


Methods for enhancing or stimulating hematopoiesis including the step of administering interleukin-12 (il-12) to yield hematopoietic recovery in a mammal in need. Preferred methods include the step of administering il-12 as an adjuvant therapy to alleviate the hematopoietic toxicities associated with one or more treatment regimens used to combat a disease state.
University Of Southern California


07/30/15
20150209407 
new patent

Methods for the treatment and prevention of osteoporosis and bone-related diseases


The present disclosure is directed to the identification that r-spondin-1 (rspo1) acts as a positive regulator of bone formation. Accordingly, the presently disclosed subject matter provides methods for treating and/or preventing osteoporosis or bone-related disorders, including administering a pharmaceutical composition of a therapeutically effective amount of an r-spondin (rspo) agonist, e.g., an rspo protein or functional fragment thereof, peptidomimetic, nucleic acid, small molecule, or other drug candidate, to a subject, e.g., a mammal.
The Trustees Of The University Of Pennsylvania


07/30/15
20150209401 
new patent

Synergistic multi-active composition for topical treatment of disorders in mammals, use of composition, and method


A synergistic composition comprising two substrates, active against many diseases of mammals, particularly humans. The substrates are particularly extracts of the aroeira plant (myracroduon urundeuva) and of the alecrim-pimenta plant (lippia sidoides)..

07/30/15
20150209339 
new patent

Hetero-substituted acetanilide derivatives as analgesic agents


Hetero-substituted acetanilide derivatives are disclosed as analgesic agents. The compounds of the invention are useful in methods for treating a disease or condition in a mammal characterized by pain and/or fever..
Janssen Pharmaceutica N.v


07/30/15
20150209280 
new patent

Fatty acid pharmaceutical foam


The present invention provides a foamable composition comprising water and an organic solvent, wherein the organic solvent comprises a fatty acid. The composition may further comprise a pharmaceutically active agent.
Stiefel Research Australia Pty Ltd


07/30/15
20150209176 
new patent

Medical device for the treatment of hemorrhoids, tissue inflammation and other conditions


This invention is directed to a medical device and a method of treating mammals, especially humans, to alleviate the symptoms, including pain, of several conditions and symptoms, including hemorrhoids, tissue inflammation and/or yeast infections, and open, draining wounds or incisions.. .

07/23/15
20150204856 

Methods to determine fluid filtration rates through mammalian luminal organs


Methods to determine fluid filtration rates through mammalian luminal organs. In one method, the method comprises the steps of positioning a segment of a mammalian luminal organ within a device, the device configured to prevent axial flow conditions through a lumen of the segment from a first end of the segment to an opposite second end of the segment, obtaining a first segment measurement at a first time, obtaining a second segment measurement at a second time, and determining a rate of fluid filtration through a wall of the segment based upon a difference between the first segment measurement and the second segment measurement and a difference in time between the first time and the second time..
Dtherapeutics, Llc


07/23/15
20150203890 

Production of sialylated n-glycans in lower eukaryotes


The present invention relates to eukaryotic host cells which have been modified to produce sialylated glycoproteins by the heterologous expression of a set of glycosyltransferases, including sialyltransferase and/or trans-sialidase, to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. Novel eukaryotic host cells expressing a cmp-sialic acid biosynthetic pathway for the production of sialylated glycoproteins are also provided.
Glycofi, Inc.


07/23/15
20150203851 

Inhibitors of bromodomain-containing protein pcaf for the treatment of autoimmune and inflammatory diseases or for the treatment of cancer


A method of treating autoimmune and inflammatory diseases or conditions or cancer in a mammal, such as a human, which comprises the administration of an inhibitor of the bromodomain-containing protein pcaf.. .
Glaxo Group Limited


07/23/15
20150203821 

Immortalized stem cell, compositions, preparations and uses thereof


The purpose of the present invention is to provide immortalized stem cells, which produce a growth factor capable of regenerating various kinds of tissues that have been damaged by a variety of causes, and a method for producing the aforesaid immortalized stem cells. Another purpose of the present invention is to provide a medicinal composition and a medicinal preparation for restoring damaged tissues, and a method for the percutaneous absorption of a culture supernatant.
Quarrymen Corporation


07/23/15
20150203811 

Sperm cell separation methods and compositions containing aptamers or nucleic acid sequences for use therein


The present invention provides an aptamer or pool of aptamers (nucleic acid sequences) that bind(s) to a target molecule on the surface, accessible from the surface or inside of a mammalian sperm cell and a method for producing the aptamers. The method comprises contacting a collection of different nucleic acid molecules with the target molecule under conditions favorable for binding between at least one of the nucleic acid molecules and the target molecule, to form at least one complex comprising the nucleic acid molecule bound to the target molecule, wherein each of the nucleic acid molecules comprises at least one segment of randomized nucleotide sequences.
Biocern, Inc.


07/23/15
20150203541 

Flagellin related polypeptides and uses thereof


The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptsis is described.. .
Cleveland Clinic Foundation


07/23/15
20150203502 

Pyrrolopyrimidine and purine derivatives


Or pharmaceutically acceptable salts thereof, wherein q, t, v, w, x, y, z, ring a, r1, r2, r3, r4, r5, r5a, r6, r7, r8, r9, r10, r11, r12, r13, r14, r15, r16, r17 and m are defined herein. There novel pyrrolopyrimidine and purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals.

07/23/15
20150203455 

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders


Wherein cy, r1, l1, r3, r4, r5, la, and ra are as defined herein. Novel benzimidazoles according to formula i, able to inhibit jak are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or hypersecretion of interferons..

07/23/15
20150202651 

Recombinant spider silk protein film and synthesizing


Methods for forming useful films using recombinant spider silk protein are discussed. In one embodiment, the method involves dissolving silk protein in a sufficient quantity to form a film suspended in a solvent.
Utah State University


07/23/15
20150202458 

Laser therapy for at least one of grade iii and grade iv capsular contracture


A method for treating at least one of grade iii capsular contracture and grade iv capsular contracture in a mammalian subject includes positioning a laser device proximate to the subject. The method also includes applying low level near infrared radiation to an area of the subject proximate to tissue in the subject experiencing at least one of grade iii capsular contracture and grade iv capsular contracture for treating the capsular contracture..
Riancorp Pty Ltd.


07/23/15
20150202427 

Device for augmenting blood flow, tissue perfusion and fluid distribution by neuromuscular stimulation in horses and other non-human mammals


The invention relates to a method and device for neuromuscular stimulation of one or more muscles, or muscle groups, with one or more beneficial effects selected from increasing arterial, venous and capillary blood flow, increasing flux of interstitial fluid and lymphatic drainage, increasing tissue oxygenation, enhancing heat distribution, enhancing the distribution of pharmaceutical products, and enhancing performance and recovery from exertion in horses.. .
Sky Medical Technology Ltd.


07/23/15
20150202408 

Medical device and delivery method onto offset surface of mammal tissue


A novel medical device and method for delivery of a scaffold for treatment of secondary lymphedema and ischemia is provided. In some embodiments a catheter medical device and magnetic guidance method are provided for delivering cell-seeded implants for guided lymphatic regeneration..
Fibralign Corporation


07/23/15
20150202401 

Conversion of nitrogen dioxide (no2) to nitric oxide (no)


A nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to generate therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal..
Geno Llc


07/23/15
20150202303 

2-iminobiotin formulations and uses thereof


The disclosure relates to improving the aqueous solubility of 2-iminobiotin. In a particular aspect, the disclosure pertains to formulations suitable for administration of 2-iminobiotin to mammals suffering from disorders or conditions that benefit from that administration..
Neurophyxia B.v.


07/23/15
20150202278 

Method of using attenuated bordetella strains


A mutated bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampg gene is provided. The attenuated mutated bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a bordetella infection.
Institut National De La Sante Et De La Recherche Medicale (inserm)


07/23/15
20150202237 

Halobacteria extracts composition for tumor reduction


A composition and method for treating solid tumors in a mammalian subject. The composition includes halobacterial extracts and dunaliella extracts, containing antioxidants.
Dr. Nona International Ltd


07/23/15
20150202218 

Broad spectrum inhibitors of the post proline cleaving enzymes for treatment of hepatitis c virus infections


Disclosed are methods of treating, inhibiting, or preventing a viral infection in a mammal in need thereof by administering a therapeutically or prophylactically effective amount of an inhibitor of fap, an inhibitor of dppiv, an inhibitor of dpp8, or an inhibitor of dpp9. The inhibitor may act as both an inhibitor of dppiv and an inhibitor of dpp8/9.
Trustees Of Tufts College


07/23/15
20150202214 

Combination of regorafenib and acetylsalicylic acid for treating cancer


The present invention relates to pharmaceutical compositions and combinations comprising regorafenib and acetylsalicylic acid, or a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof or a polymorph thereof for treating, preventing or managing diseases and conditions including hyperproliverative disorders such as cancer in humans and other mammals.. .
Bayer Ag


07/23/15
20150202180 

Pharmaceutical compositions of anisomelic acid and the use thereof


A pharmaceutical composition for anti-viral cancer treatment in mammals, comprising a therapeutically effective amount of anisomelic acid or salts thereof. The pharmaceutical composition may comprise anisomelic acid or salt thereof in an oil-in-water emulsion, for example in an isotropic mixture of at least one oil and at least one surfactant or, alternatively, in a hydrophilic solvent and a co-solvents or surfactant or a combination thereof.

07/23/15
20150202178 

Compositions and methods of use of phorbol esters


Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like hiv and aids, or the development of neoplasms in a mammalian subject.

07/23/15
20150202176 

Compositions for prevention/prophylactic treatment of poison ivy dermatitis


Tolerizing and desensitizing mammals, including humans, to allergens contained in plants of the anacardiaceae and ginkgoaceae families is attained by administering a composition containing at least one water soluble urushiol ester compound.. .

07/23/15
20150202164 

Oral rapamycin nanoparticle preparations


Oral preparations of microcapsules and nanoparticles including an inhibitor of the mammalian target of rapamycin. The preparations are intended to assist with the treatment and prevention of cancer neurocognitive dysfunction, genetically predisposed disorders, and age-related disorders.

07/23/15
20150202063 

Graft devices and related systems and methods


In some aspects, graft devices for a mammalian patient can include a tubular member comprising a first end; and a fiber matrix surrounding the tubular member, wherein the fiber matrix is designed and constructed to be substantially continuously tapered at the first end to define a diameter that increases as it approaches the first end.. .
Neograft Technologies, Inc.


07/23/15
20150201896 

Method and system for automated detection of tissue interior to a mammalian ribcage from an in vivo image


Described herein are systems and methods for efficient and accurate, automated detection of a region of interest interior to the ribcage from an in vivo mammalian image. It is found that efficient, automated identification of the region of interest interior to the ribcage can be achieved by the use of both a bone distance mask and a surface distance mask.
Perkinelmer Cellular Technologies Germany Gmbh


07/23/15
20150201868 

Method and measuring reaction forces


Apparatus is disclosed for monitoring, measuring and/or estimating a force applied to a body or body part of a vertebral mammal. The apparatus includes an acceleration sensor for measuring acceleration of the body or body part relative to an inertial frame of reference and for providing data indicative of the acceleration.
Dorsavi Pty Ltd


07/23/15
20150201588 

Autologous mammalian models derived from induced pluripotent stem cells and related methods


Disclosed is an autologous non-human mammalian model system derived from induced pluripotent stem (ips) cells. Also disclosed are methods of differentiating non-human primate ips cells, which can result in populations of cells enriched for sox2+ or pdx1+ foregut-like cells, for cdx2+ hindgut-like cells, for cd34+ hematopoietic progenitor-like cells, or epithelial-like cells.
Amgen Inc.


07/16/15
20150197772 

Mammalian expression vector puhab


The present invention relates to the construction and utilization of a new mammalian expression vector that contains a unique multiple cloning site (mcs), designated puhab. The puhab vector comprises a high copy replication origin (cole1), a drug resistance gene (tk-hygromycin), and a human cytomegalovirus promoter operably associated with a unique intron (hcmv/intron).
Merck Sharp & Dohme Corp.


07/16/15
20150197748 

Oral delivery of nucleic acid-based gene interfering agents by salmonella


The present invention provides vectors, including a novel attenuated strain of salmonella, for efficient gene transfer into an animal, e.g. A mammalian host..
The Regents Of The University Of California


07/16/15
20150197572 

Immunopotentiative composition


Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by pd-1, pd-l1, or pd-l2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of pd-1, pd-l1, or pd-l2 are useful for cancer or infection treatment..
Tasuku Honjo


07/16/15
20150197536 

Compounds reducing the production of sorbitol in the eye and methods of using the same


Methods of inhibiting the progression of or treating secondary complications of diabetes, especially a diabetic eye disease, in a mammal by inhibiting the production of sorbitol in the mammal. Small molecule inhibitors of sorbitol production in the eye useful in the methods of the invention and pharmaceutical compositions containing the compounds, and methods of using the same..
The Regents Of The University Of Colorado, A Body Corporate


07/16/15
20150197517 

Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases


The present invention relates to novel thiazole-substituted indolin-2-ones as inhibitors of cscpk and related kinases; to methods of inhibiting cancer stem cells by using a kinase inhibitor; to pharmaceutical compositions containing such compounds; and to methods of using such compounds in the treatment of a protein kinase related disorder in a mammal; and to processes of making such compounds and intermediates thereof.. .
Boston Biomedical, Inc.


07/16/15
20150197506 

Novel benzopyran compounds, compositions and uses thereof


Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are op-1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3r)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2h-chromen-7-ol, and op-1074, which is (2s)-3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3r)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2h-chromen-7-ol. Op-1074 is a pure anti-estrogen when tested in the agonist mode and a complete anti-estrogen when tested in the antagonist mode.
Olema Pharmaceuticals, Inc.


07/16/15
20150197484 

Use of cannabidiol prodrugs in topical and transdermal administration with microneedles


Described herein are microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug delivery systems comprising pharmaceutical compositions, comprising cannabidiol and prodrugs of cannabidiol, and microneedle arrays in the treatment disease, including pancreatitis and pancreatic cancer..
Zynerba Pharmaceuticals, Inc.


07/16/15
20150197478 

Compositions and methods of use of phorbol esters for treatment of stroke


Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects..

07/16/15
20150197458 

Process for the production of a product based on faecals produced by animals as well as a plant for the production of the product, especially a fertilizer product


The present disclosure relates to a process for producing a product based on faecals produced by animals, characterized in that faecals from mammals are wholly or partially dissolved using an oxidizing acid, solid acid-insoluble components are separated, if necessary, and the liquid component is neutralized with a base. Moreover, the invention relates to a plant for producing a product, the plant comprising a faecal reactor for receiving animal faecals, wherein the reactor is provided with means for supplying an oxidizing acid, possibly a separator unit for separating solid, acid-insoluble components, and a neutralizing reactor for neutralizing the part of the faecals dissolved by means of the oxidizing acid, wherein the neutralizing reactor is provided with means for supplying a base.
Waste 2 Green, Llc


07/16/15
20150196774 

Laser immunotherapy


A method of immunotherapy of a mammal or a laser device therefor, includes the step of treating one or more immune privileged cells, tissue or organs of said mammal with a laser to reduce or eliminate the immune privilege status of said one or more cells, tissues and/or organs to thereby elicit an immune response that is beneficial to the mammal. The method of immunotherapy avoids or minimizes lasting damage to the treated cells, tissues and/or organs.
Ellex Medical Pty Ltd.


07/16/15
20150196651 

Lipidated peptides for lowering blood glucose


Lipidated analogs of prolactin-releasing peptides (prrp) and their use in controlling and lowering blood glucose in mammals is disclosed. Useful compounds included lipidated analogs of prrp20 and prrp31.
Fyziologicky Ustav Akademie Ved Cr, V.v.i.


07/16/15
20150196629 

Immunogenic compositions of staphylococcus epidermidis polypeptide antigens


The present invention relates to immunogenic compositions, comprising polypeptides isolated from staphylococcus epidermidis. The invention also relates to polynucleotides encoding staphylococcus epidermidis polypeptides and their use in immunogenic compositions.
Wyeth Llc


07/16/15
20150196613 

Saffron treatment mammalian maladies


A variety of medicinal compounds comprising crocus sativus for the treatment of a plurality of medical ailments are described. A method of creating a crocus sativus extract is also described.

07/16/15
20150196538 

Therapeutic agent for dyslipidemia


The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low hdl blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc.
Kowa Company, Ltd.


07/16/15
20150196524 

Composition and the protection of articular cartilage


The novel therapeutic potential of calebin a and compositions thereof to prevent pathological damage to mammalian articular cartilage is disclosed.. .

07/16/15
20150196374 

Oral care systems


An oral care system that provides a beneficial effect to an oral cavity of a mammal by using a liquid effective for providing the beneficial effect, where the system includes means for directing the liquid onto a plurality of surfaces of the oral cavity, means for providing the liquid to the means for directing the liquid onto the surfaces of the oral cavity, means for providing reciprocation of the liquid over the plurality of surfaces under conditions effective to provide the beneficial effect; and a reservoir for containing the liquid.. .
Mcneil-ppc, Inc.


07/09/15
20150191789 

Methods and materials for identifying mammals having prostate cancer


This document provides methods and materials related to identifying prostate cancer in male mammals. For example, methods and materials for assessing a benign prostate sample (e.g., benign prostate tissue or cells) to determine whether or not a mammal has prostate cancer are provided..
Mayo Foundation For Medical Education And Research


07/09/15
20150191768 

Self-immolative probes for enzyme activity detection


In this compound, sig is a signaling molecule, si is a self-immolative structure bound to sig such that sig has a reduced signal relative to the signal of sig without si, mod is a moiety bound to si that is subject to modification by an activator, and m is an integer from 1 to about 10. With this compound, when mod is modified by an activator, si is destabilized and self cleaved from sig such that sig generates an increased signal.

07/09/15
20150191732 

Lepidopteran insect n-acetylglucosaminidase genes and their use in glycoengineering


A transgenic insect cell line for production of elevated levels of recombinant glycoproteins comprising mammalian-like n-glycans is provided. Also disclosed is a nucleic acid sequence encoding n-acetylglucosaminidase..
University Of Wyoming


07/09/15
20150191704 

Poxvirus-plasmodium recombinants, compositions containing such recombinants, uses thereof, and methods of making and using same


The invention provides a recombinant or synthetic or engineered or non-naturally occurring poxvirus that contains and expresses dna encoding a heterologous or exogenous antigen, epitope or immunogen and flagellin or an operable binding portion thereof. The poxvirus can contain or be engineered to contain and express vaccinia host range gene k1l.

07/09/15
20150191547 

Human anti-kir antibodies


Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of nk cells and allow a potentiation of nk cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7f9 or 1-4f1.
University Of Genoa


07/09/15
20150191527 

Methods of treating alzheimer's disease with apo a-1 milano


This invention relates to the treatment of alzheimer's disease, the reduction of the progression of alzheimer's disease, and the alleviation of symptoms of alzheimer's disease by administering apoa-1 milano based therapies to provide anti-inflammatory, antioxidant, and lipid depleting effects to brain tissue. In particular embodiments, the method comprises administering a composition comprising an raav vector encoding apoa-1 milano or an active fragment thereof, to a mammal having alzheimer's disease or a symptom of alzheimer's disease..
Cedars-sinai Medical Center


07/09/15
20150191524 

Engineering t cell receptors


The use of model t cell receptors (tcrs) as scaffolds for in vitro engineering of novel specificities is provided. Tcrs with de novo binding to a specific peptide-major histocompatibility complex (mhc) product can be isolated by: 1) mutagenizing a t cell receptor protein coding sequence to generate a variegated population of mutants (a library), 2) selection of the library of tcr mutants with the specific peptide-mhc, using a process of directed evolution and a “display” methodology (e.g., yeast, phage, mammalian cell) and the peptide-mhc ligand.
The Board Of Trustees Of The University Of Illinoi


07/09/15
20150191517 

Novel sodium channel blocking peptides and the use thereof


The present invention relates to c-terminal modified protoxin ii peptides that selectively inhibit the nav1.7 sodium channel; the present invention also relates to pharmaceutical compositions useful for prophylactic or therapeutic treatment of a disorder responsive to the blockade of sodium ion channels, especially nav1.7 sodium ion channels; the present invention further provides methods of treating a disorder responsive to the blockade of sodium channels, and particularly nav1.7 sodium channels, in a mammal suffering from excess activity of said channels.. .
Purdue Pharma L.p.


07/09/15
20150191484 

Novel compounds having a tetracyclic iridoid skelton and an anti-trypanosomal agent comprising the same as an active ingredient


The present invention provides anti-trypanosomal agent for treating, preventing trypanosomiasis of mammals, which comprises a compound having the tetracyclic iridoid skeleton represented by a general formula (i).. .
Nagasaki International University


07/09/15
20150191476 

Imidazotriazinone compounds


The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9 and pharmaceutically acceptable salt thereof. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of pde9 associated diseases or disorders in mammals, including humans..
Forum Pharmaceuticals, Inc.


07/09/15
20150190620 

Implantable system for collection and supply of interstitial fluid


A system for redistributing interstitial fluid within a mammal is disclosed. The system comprises an implantable accumulation chamber, a confined flow passageway such as a catheter in communication with the accumulation chamber, and a liquid transfer pump for dispensing accumulated interstitial fluid from the accumulation chamber to a predetermined body site via the confined flow passageway..

07/09/15
20150190547 

Bone matrix compositions and methods


An osteoinductive composition, corresponding osteoimplants, and methods for making the osteoinductive composition are disclosed. The osteoinductive composition comprises osteoinductive factors, such as may be extracted from demineralized bone, and a carrier.
Warsaw Orthopedic, Inc.


07/09/15
20150190544 

Solid polyglycol-based biocompatible pre-formulation


Provided herein are pre-formulations forming a biocompatible hydrogel polymer comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the biocompatible hydrogel polymer covers a wound in a mammal and adheres to the surrounding skin tissue.
Medicus Biosciences Llc


07/09/15
20150190459 

Method of reducing injury to mammalian cells


A method of inhibiting the binding between n-methyl-d-aspartate receptors and neuronal proteins in a neuron is disclosed. The method comprises administering to the neuron an effective inhibiting amount of a peptide replacement agent for the nmda receptor or neuronal protein interaction domain that effect said inhibition of the nmda receptor-neuronal protein interaction.
Nono Inc.


07/09/15
20150190435 

Synergistic bacterial compositions and methods of production and use thereof


Provided are therapeutic compositions containing ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.. .
Seres Health, Inc.


07/09/15
20150190419 

Method to treat or prevent herpesvirus infections


Methods and compositions are provided for inhibiting or treating a herpesvirus infection in a subject using inhibitors of mammalian akt.. .
Albert Einstein College Of Medicine Of Yeshiva University


07/09/15
20150190396 

Treatment of type i and type ii diabetes


The present invention provides methods of treating type i or type ii diabetes in a mammal by administering an effective amount of insulin and an effective amount of a phenoxypyrimidinone compound to the mammal in need of such treatment, and formulations for carrying out the methods.. .
Melior Pharmaceuticals L, Inc.


07/09/15
20150190364 

Sparc and methods of use thereof


The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the sparc protein or rna in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or rna from the tumor, a sparc protein or rna detection and quantification means, control rnas, and rules for predicting the response of the tumor based on the level of sparc protein or rna in tumor..
Abraxis Bioscience, Llc


07/09/15
20150190346 

Compositions and methods for treatment of abnormal cell growth


This invention relates to oral dosage forms and methods that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.. .
Pfizer, Inc.


07/09/15
20150190166 

Methods and systems for submucosal implantation of a device for diagnosis and treatment of a body


Instruments, systems and methods are provided for performing submucosal medical procedures in a desired area of the digestive tract using endoscopy. Instruments include a safe access needle injection instrument and a submucosal tunneling instrument, a submucosal dissection instrument, and a mucosal resection device.
Apollo Endosurgery, Inc.


07/02/15
20150184165 

Immunosuppression compound and treatment method


A method and compound for suppressing an immune response in a mammalian subject, for the treatment or prevention of an autoimmune condition or transplantation rejection are disclosed. The compound is an antisense oligonucleotide analog compound having a targeting sequence complementary to a preprocessed ctla-4 mrna region identified by seq id no: 22 in seq id no: 1, spanning the splice junction between intron 1 and exon 2 of the preprocessed mrna of the subject.
Sarepta Therapeutics, Inc.


07/02/15
20150184138 

Plant-based recombinant butyrylcholinesterase production methods


A new, reliable, easily scalable and reproducible method for the production of recombinant butyrylcholinesterase (rbuche) is provided. Through the utilization of a plant transfection procedure, various plant strains have been shown to generate effective and scalable amounts of rbuche under acceptable manufacturing processes to permit reliable levels of such enzymes for desired nerve agent protection requirements (including tetrameric products).

07/02/15
20150183871 

Antibodies against the rgm a protein and uses thereof


The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize rgm a protein. Specifically, these antibodies have the ability to inhibit the binding of rgm a to its receptor and/or coreceptors.
Abbvie Inc.


07/02/15
20150183850 

Methods and compositions for treating amyloid deposits


The present disclosure provides methods of delivering a protective apoe isoform to the central nervous system of a mammal, comprising administering to the cerebrospinal fluid (csf) of the mammal an raav particle comprising an aav capsid protein and a vector comprising a nucleic acid encoding the protective apoe isoform inserted between a pair of aav inverted terminal repeats in a manner effective to infect ependymal cells in the non-rodent mammal such that the ependymal cells secrete the apoe into the csf of the mammal.. .
The General Hospital Corporation


07/02/15
20150183843 

Glycoproteins having lipid mobilising properties and therapeutic applications thereof


A biologically active lipid mobilising agent for use in therapy is disclosed which has the properties and characteristics of a zn-α2-glycoprotein, or of a fragment thereof having an apparent molecular mass mr greater than 6.0 kda as determined by gel exclusion chromatography. Methods of isolation and purification from biological material are also disclosed together with uses of the material for making up pharmaceutical compositions, especially pharmaceutical compositions useful for treating mammals to achieve weight reduction or for controlling obesity.
Aston University


07/02/15
20150182681 

Ambulatory lung assist device with implanted blood pump and oxygenator


The present disclosure provides a system for oxygenating blood. The system may include an implantable blood pump that may draw a supply of blood from the circulatory system of a mammalian subject, such as a human being.
Heartware, Inc.


07/02/15
20150182638 

Virus-mediated delivery of bevacizumab for therapeutic applications


The invention provides a method of inhibiting ocular neovascularization in a mammal by administering a composition comprising a bevacizumab-encoding adeno-associated virus (aav) vector directly to the eye of the mammal.. .
Cornell University


07/02/15
20150182637 

Widespread gene delivery of gene therapy vectors


The present invention relates to improved compositions and methods for delivering and expressing therapeutic genes in mammals. More particularly, the invention stems from the unexpected discovery that a remarkable, massive and widespread therapeutic gene delivery and expression is obtained in mammals when a therapeutic gene is incorporated in a viral vector and administered both into the csf and into the blood of the mammal.
Association Institut De Myologie


07/02/15
20150182636 

Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents


The invention provides methods of preventing or treating diseases or disorders caused by biological agents or chemical agents in a subject (e.g., a mammal, such as a human) by administering genetically modified human umbilical cord perivascular cells.. .
Tissue Regeneration Therapeutics Inc.


07/02/15
20150182621 

Compositions and methods for enhancing antigen-specific immune responses


Methods for treating or preventing recurrence of hyper proliferating diseases, e.g., cancer and persistent viral infections, are described. A method may comprise priming a mammal by administering to the mammal an effective amount of a nucleic acid composition encoding an antigen or a biologically active homolog thereof and boosting the mammal by administering to the mammal an effective amount of an oncolytic virus comprising a nucleic acid encoding the antigen or the biologically active homolog thereof..
The Johns Hopkins University


07/02/15
20150182617 

Glycoproteins for pseudotyping lentivectors


The invention relates to compositions and methods based on the use of viral g proteins to pseudotype vectors. The viral g proteins can be expressed by expression vectors and can be used to pseudotype lentiviral vectors.
Theravectys


07/02/15
20150182612 

Compositions and methods for treating an active mycobacterium tuberculosis infection


The present disclosure relates to methods and compositions for treating a active tuberculosis infection and methods and compositions for improving the efficacy of chemotherapy regimens against active tuberculosis infection. The present disclosure relates to methods of treating an active m.
Infectious Disease Research Institute


07/02/15
20150182587 

Methods for treating reperfusion injuries


The present invention relates to treating a tissue in a mammal from the effects of reperfusion using flagellin. .
Cleveland Clinic Foundation


07/02/15
20150182549 

Method for enzymatic glycosylation of oligosaccharides from mammalian animal milk


A method for modifying galactosyl disaccharides in order to enhance their bifidogenic effect, comprising reacting at least one glycosyl donor with a precursor galactosyl disaccharide or a mixture of precursor galactosyl disaccharides using enzyme catalysis, compounds obtainable by said method and the use of such compounds in consumable products.. .
Glycom A/s


07/02/15
20150182515 

Methods for treating obesity and disorders associated with hyperlipidemia in a mammal


The disclosure relates to methods for treating hyperlipidemia in a mammal. The present disclosure also relates to methods for treating and/or controlling obesity in a mammal.
Aegerion Pharmaceuticals, Inc.


07/02/15
20150182500 

Compositions for use in treating or preventing metabolic stress-induced lung injury and methods for increasing physical capacity of mammalian livestock


The present invention relates to a composition comprising (i) choline and (ii) a compound selected from the group consisting of palmitate, vitamin c and vitamin e for use in treating or preventing metabolic stress-induced lung injury and a method for increasing physical capacity of mammalian livestock comprising administering to the mammalian livestock the above composition.. .
Nutri-fit Gmbh & Co. Kg


07/02/15
20150182453 

Methods and compositions for enhancing the viability of microneedle pores


Described herein is a method of transdermally administering one or more pharmaceutically active agents to a mammal. The method comprises administering one or more active pharmaceutical agents to the skin of the subject, in conjunction with microneedles and one or more cox inhibitors, whereby the cox inhibitors facilitate the absorption of the active pharmaceutical agents by prolonging the pore opening created by the application of the microneedle..
Aiitranz Inc.


07/02/15
20150182415 

Eyelid care appliance


Disclosed herein is an improved eyelid care appliance and method of using such appliance for preventing and treating blepharitis and mammalian meibomian gland dysfunction caused by gland obstruction. The method and apparatus of the invention enable restoration and maintenance of eyelid hygiene and the natural flow of secretions from the meibomian glands.



Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Mammal for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Mammal with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.5836

4979

459570 - 0 - 118